NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Gensaic

Gensaic

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://gensaic.com/

Last Round

Collaboration Agreement

Mar 3, 2025

Total Funding Raised

$3.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gensaic is a biotechnology company that has developed a machine-guided protein design platform to create tissue-selective, intracellular therapies for metabolic and age-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

protein designdrug deliveryAI drug discoveryin vivo deliverysiRNAgene therapyphage displayprecision medicineRNA therapeuticsbiotech platformgenerative biologytissue targetingin silico designdelivery vehicleRNAi

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gensaic Comparables

Compare Gensaic with similar companies based on industry and business-model similarity.

Gensaic comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Senda Biosciences
81%
Sail Biomedicines
78%
Entos Pharmaceuticals
78%

Gensaic Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Collaboration AgreementMar 3, 2025
GrantJan 9, 2023
VC RoundAug 24, 2022

Key People

Founding team and executive leadership

Jonathan Hsu

Chief Technology Officer & Co-Founder

Founding Team

Lavi Erisson

CEO And Cofounder

Founding Team

Gensaic Investors

Notable investors and investment history

Gensaic investors
InvestorRounds
Cystic Fibrosis FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Grew 23% QoQ, from 13 to 16 employees.

  • Mar 3, 2025

    Secured a Collaboration Agreement round of funding.

Gensaic Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gensaic Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gensaic's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range16
Year Founded2020
Last FundingMar 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.